Status:
COMPLETED
Fatigue Prevalence, Severity, and State of Treatment in Germany
Lead Sponsor:
German Cancer Research Center
Conditions:
Cancer-related Fatigue
Eligibility:
All Genders
18+ years
Brief Summary
Fatigue is a major concern during and after cancer therapy with severe impact on quality of life. Yet, sound comparable data on fatigue prevalence, severity, and impact on daily life across different ...
Eligibility Criteria
Inclusion
- ≥ 18 years of Age
- Diagnosed with a primary tumor of one of the following malignant neoplasms (including in-situ carcinoma): stomach (C16, D00.2), colon (C18, D01.0), rectum (C19-20, D01.1-1.2), liver (C22, D01.5), pancreas (C25, D01.7), lung (C33-34, D02.1-2.2), malignant melanoma (C43, D03), breast (C50, D05, female only), cervix or ovaries (C53, D06), endometrium (C54.1, D07.0), ovaries (C56), prostate (C61), kidney (C64), bladder (C67, D09.0), non-Hodgkin lymphoma (C82-88), leukemia (C91-C95)
- Time since first diagnosis is at least 1 year, maximal 2 years
- Able to understand and follow the study protocol.
Exclusion
- • Any additional malignant or unclear neoplasm or carcinoma in situ at or since time of diagnosis of the considered primary tumor, except non-malignant, unspecified, or in-situ neoplasm of skin (C44 or D0.4)
Key Trial Info
Start Date :
November 30 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2021
Estimated Enrollment :
2508 Patients enrolled
Trial Details
Trial ID
NCT03318224
Start Date
November 30 2017
End Date
April 30 2021
Last Update
December 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
German Cancer Research Center
Heidelberg, Germany, 69120